Pharmacyclics (PCYC) Earning Somewhat Favorable Media Coverage, Report Finds
News headlines about Pharmacyclics (NASDAQ:PCYC) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pharmacyclics earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.8359845299177 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
ILLEGAL ACTIVITY WARNING: “Pharmacyclics (PCYC) Earning Somewhat Favorable Media Coverage, Report Finds” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/pharmacyclics-pcyc-earning-somewhat-favorable-media-coverage-report-finds/1776544.html.
Pharmacyclics, Inc is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer.
Receive News & Ratings for Pharmacyclics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyclics and related companies with MarketBeat.com's FREE daily email newsletter.